Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
4.11 ^USD	+5.38%		+1.23%	-24.17%

May. 02	HC Wainwright Starts Sagimet Biosciences With Buy Rating, $32 Price Target	MT
Apr. 25	Certain Warrants of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	CI

Certain Warrants of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.

April 24, 2024

Certain Warrants of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024. These Warrants will be under lockup for 91 days starting from 25-JAN-2024 to 25-APR-2024.

Details:
The our directors, executive officers and certain of our stockholders have agreed that for a period of 90 days following the date of this prospectus

Latest news about Sagimet Biosciences Inc.

HC Wainwright Starts Sagimet Biosciences With Buy Rating, $32 Price Target	May. 02	MT
Certain Warrants of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	Apr. 24	CI
Certain Options of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	Apr. 24	CI
Certain Series A Common Stock of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	Apr. 24	CI
Sagimet Biosciences Inc. Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat	Mar. 27	CI
Goldman Sachs Adjusts Sagimet Biosciences' Price Target to $27 From $37, Maintains Buy Rating	Mar. 26	MT
Leerink Partners Initiates Sagimet Biosciences With Outperform Rating, $26 Price Target	Mar. 25	MT
Sagimet Biosciences Inc. Announces Management Changes	Mar. 25	CI
Sagimet Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
JMP Securities Adjusts Price Target on Sagimet Biosciences to $46 From $47, Maintains Market Outperform Rating	Feb. 07	MT
Top Premarket Decliners	Jan. 26	MT
Sagimet Biosciences Prices $112.5 Million Common Stock Offering; Shares Fall Pre-Bell	Jan. 26	MT
Sagimet Biosciences Launches Public Offering of Series A Common Shares	Jan. 24	MT
Goldman Sachs Raises Price Target on Sagimet Biosciences to $37 From $30, Keeps Buy Rating	Jan. 23	MT
JMP Securities Raises Price Target on Sagimet Biosciences to $47 From $31, Maintains Market Outperform Rating	Jan. 23	MT
Sector Update: Health Care Stocks Advance Late Afternoon	Jan. 22	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Jan. 22	MT
Top Midday Gainers	Jan. 22	MT
Sagimet Shares Climb After Positive Results From Study of NASH Treatment Denifanstat	Jan. 22	MT
Sagimet's shares hit new high as fatty liver disease drug shows promise in study	Jan. 22	RE
Sagimet's fatty liver disease drug shows promise in trial	Jan. 22	RE
Sagimet Biosciences Announces Positive Topline Results from Phase 2B Fascinate-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 Nash	Jan. 22	CI
Certain Options of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 10-JAN-2024.	Jan. 09	CI
Certain Series A Common Stock of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 10-JAN-2024.	Jan. 09	CI
Certain Series B Common Stock of Sagimet Biosciences Inc. are subject to a Lock-Up Agreement Ending on 10-JAN-2024.	Jan. 09	CI

Chart Sagimet Biosciences Inc.

Duration

Period

More charts

Company Profile

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In addition to MASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase III clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.32 USD

Average target price

40 USD

Spread / Average Target

+825.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SAGIMET BIOSCIENCES INC.	-24.17%	138M
MODERNA, INC.	+25.69%	47.86B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.66B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
BIO-TECHNE CORPORATION	+0.17%	12.15B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research